Fortress Biotech, Inc. has 3 Schedule 13D or 13G filings on record since 2026-03-20. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | 20.7% | 6,917,715 | SCHEDULE 13D/A, 2026-03-20 | 2026-03-18 |
| Highbridge Capital Management, LLC | 7.8% | 2,734,654 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Integrated Core Strategies (US) LLC | 5.3% | 1,778,133 | SCHEDULE 13G, 2026-09-01 | 2026-08-26 |
Purpose of Transaction (Item 4)
Lindsay A. Rosenwald, M.D.
The Reporting Person was granted the shares of Common Stock on each of January 1, 2025 and March 18, 2026 pursuant to the LTIP and Award Agreement and upon the determination that the Reporting Person had achieved 100% of the relevant goals and objectives established by the Compensation Committee of the Issuer's Board. The Reporting Person does not have any present plans or proposals that relate to or would result in: (i) the acquisition by any person of additional securities of Issuer, or the disposition of securities of Issuer; (ii) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving Issuer or any of Issuer's subsidiaries; (iii) a sale or transfer of a material amount of assets of Issuer or any of Issuer's subsidiaries; (iv) any change in the present board of directors or management of Issuer; (v) any material change in the present capitalization or dividend policy of Issuer; (vi) any other material change in Issuer's business or corporate structure; (vii) changes in Issuer's charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of Issuer by any person; (viii) causing a class of securities of Issuer to be de-listed from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association; (ix) a class of equity securities of Issuer becoming eligible for termination of registration …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-20 | Lindsay A. Rosenwald, M.D. | 20.7% | SCHEDULE 13D/A |
| 2026-05-15 | Highbridge Capital Management, LLC | 7.8% | SCHEDULE 13G/A |
| 2026-09-01 | Integrated Core Strategies (US) LLC | 5.3% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Fortress Biotech, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.